S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
First-Time Investor? Here Are 9 Mistakes You Want To Avoid
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Ford Stock Going Forward After Big Earnings Flop
Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Closing prices for crude oil, gold and other commodities
AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Indian tycoon Adani hit by more losses, calls for probe
Ford, Starbucks fall; Clorox, Gilead Sciences rise
NASDAQ:REGN

Regeneron Pharmaceuticals - REGN Stock Forecast, Price & News

$783.13
+31.93 (+4.25%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$758.63
$789.95
50-Day Range
$680.49
$766.39
52-Week Range
$538.01
$789.95
Volume
1.45 million shs
Average Volume
631,572 shs
Market Capitalization
$85.28 billion
P/E Ratio
16.51
Dividend Yield
N/A
Price Target
$798.65

Regeneron Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
2.0% Upside
$798.65 Price Target
Short Interest
Healthy
1.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.68
Upright™ Environmental Score
News Sentiment
0.84mentions of Regeneron Pharmaceuticals in the last 14 days
Based on 32 Articles This Week
Insider Trading
Selling Shares
$14.07 M Sold Last Quarter
Proj. Earnings Growth
-2.52%
From $37.73 to $36.78 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

150th out of 1,029 stocks

Pharmaceutical Preparations Industry

64th out of 501 stocks

REGN stock logo

About Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Stock News Headlines

Four Undervalued Healthcare Stocks for 2023 (REGN)
These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.
Bank of America Securities Keeps Their Sell Rating on Regeneron (REGN)
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Regeneron Pharmaceuticals Q4 Profit Declines
Regeneron Pharma Q4 Profit Declines; Adj. Total Revenues Up 14%
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Regeneron profit beats estimates on Dupixent strength
Time to Buy Cigna or Regeneron Stock Before Earnings?
Regeneron (REGN) Stock Moves -0.86%: What You Should Know
See More Headlines
Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REGN Company Calendar

Last Earnings
2/03/2023
Today
2/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:REGN
CUSIP
75886F10
Employees
10,368
Year Founded
1988

Price Target and Rating

Average Stock Price Forecast
$798.65
High Stock Price Forecast
$970.00
Low Stock Price Forecast
$625.00
Forecasted Upside/Downside
+2.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
20 Analysts

Profitability

Net Income
$8.08 billion
Pretax Margin
44.04%

Debt

Sales & Book Value

Annual Sales
$16.07 billion
Cash Flow
$84.30 per share
Book Value
$172.92 per share

Miscellaneous

Free Float
99,112,000
Market Cap
$85.28 billion
Optionable
Optionable
Beta
0.25

Social Links


Key Executives

  • Leonard S. SchleiferLeonard S. Schleifer
    Co-President, Chief Executive Officer & Director
  • George Damis YancopoulosGeorge Damis Yancopoulos
    Co-President, Director & Chief Scientific Officer
  • Patrice Gilooly
    Senior VP-Quality Assurance & Operations
  • Robert E. LandryRobert E. Landry
    Chief Financial Officer & Executive VP-Finance
  • Neil StahlNeil Stahl
    Executive VP-Research & Development













REGN Stock - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REGN shares.
View REGN analyst ratings
or view top-rated stocks.

What is Regeneron Pharmaceuticals' stock price forecast for 2023?

20 brokerages have issued 1 year target prices for Regeneron Pharmaceuticals' shares. Their REGN share price forecasts range from $625.00 to $970.00. On average, they expect the company's stock price to reach $798.65 in the next year. This suggests a possible upside of 2.0% from the stock's current price.
View analysts price targets for REGN
or view top-rated stocks among Wall Street analysts.

How have REGN shares performed in 2023?

Regeneron Pharmaceuticals' stock was trading at $721.49 at the start of the year. Since then, REGN shares have increased by 8.5% and is now trading at $783.13.
View the best growth stocks for 2023 here
.

When is Regeneron Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 3rd 2023.
View our REGN earnings forecast
.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its earnings results on Friday, February, 3rd. The biopharmaceutical company reported $12.56 EPS for the quarter, topping the consensus estimate of $8.33 by $4.23. The biopharmaceutical company earned $3.41 billion during the quarter, compared to analysts' expectations of $3.11 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 31.16% and a net margin of 39.17%. The business's quarterly revenue was down 31.1% compared to the same quarter last year. During the same period in the previous year, the company earned $23.72 earnings per share.

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Sustainable Growth Advisers LP (0.40%), Sumitomo Mitsui Trust Holdings Inc. (0.35%), New York State Common Retirement Fund (0.17%), DekaBank Deutsche Girozentrale (0.16%), New York State Teachers Retirement System (0.11%) and Assenagon Asset Management S.A. (0.11%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends
.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $783.13.

How much money does Regeneron Pharmaceuticals make?

Regeneron Pharmaceuticals (NASDAQ:REGN) has a market capitalization of $85.28 billion and generates $16.07 billion in revenue each year. The biopharmaceutical company earns $8.08 billion in net income (profit) each year or $47.43 on an earnings per share basis.

How many employees does Regeneron Pharmaceuticals have?

The company employs 10,368 workers across the globe.

Does Regeneron Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More
How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The official website for the company is www.regeneron.com. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at invest@regeneron.com, or via fax at 914-347-2113.

This page (NASDAQ:REGN) was last updated on 2/4/2023 by MarketBeat.com Staff